Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Gilead Sciences (GILD), an HIV and hepatitis C drugmaker, is a trending stock with mixed fundamentals. The company maintains a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the broader market. While Gilead has beaten consensus estimates in the last four quarters and shows modest revenue growth forecasts of 4.4% and 6.1% for the current and next fiscal years, earnings estimates remain challenged with a projected -105.9% year-over-year change for the current fiscal year. The stock is valued at par with its peers.